Introduction
Primary Sjögren's syndrome (SS) is an autoimmune chronic disease, characterized by progressive destruction of exocrine glands, mainly salivary and lacrimal, producing the characteristic symptoms of the disease: mouth dryness (xerostomia) and eye dryness (keratoconjuntivitis sicca; Daniels & Talal, 1987; Manthrope et al, 1986; Vitali et al, 1993) .
Various factors may influence the appearance of SS: (1) as most autoimmune diseases, women around 50 y of age are more susceptible to develop SS than men, suggesting that female sex hormones may play an important role in the etiology of this disease (Ahmed et al, 1985; Bhalla, 1989);  (2) there is also a close association of SS with antigens of the major histocompatibility complex, mainly haplotype B8-DR3-SCO1 (Alarcó n- Segovia, 1989; Reveille, 1992) , with factor C4 of the complement system (Alarcó n-Segovia, 1989; Moriuchi et al, 1991) , and with alterations of the immunoregulatory circuits of B and T cells (Alarcó n-Segovia, 1989) ; (3) on the other hand, the presence of certain viral diseases can be linked to its etiology (Kater & deWilde, 1992; Salvarani et al, 1991) .
Nutrition and nutritional status can produce deep effects on the immune system's function, infection resistance and autoimmunity in humans and animals. Nutrients increase or depress functions of the immune system depending on the specific nutrient and its amount in the diet. Nutrients such as vitamins A and E, some lipids, and minerals, such as zinc, copper and selenium, regulate the immune response (Harbige, 1996) . Vitamin A affects T-cell subpopulations, as well as the synthesis of some cytokines and antibody subclasses, whereas supplementation with vitamin E increases the number of CD4 þ cells (Harbige, 1996) . Lipids, especially essential fatty acids, can modify autoimmune diseases by altering the synthesis of prostaglandins (Horrobin, 1986) . The water soluble vitamin pyridoxine (B 6 ) is also associated with the immune response (Beisel, 1982; Beisel, 1990; Chandra et al, 1981; Chandra, 1991) . Deficiency of this vitamin induces atrophy of lymphoid organs (Beisel, 1982; Chandra et al, 1981; Chandra, 1991) , reduces lymphocyte production, and alters antibody response and interleukin 2 (IL-2) production (Meydani et al, 1991; Rall & Meydani, 1993; Trakatellis et al, 1992) .
SS patients show abnormal humoral and cellular immune responses. It has been demonstrated that these patients also show alterations in the cytokine profiles in vivo and in vitro, as well as in the response of immunocompetent cells to these factors. Furthermore, supernatants of mononuclear cells from SS patients stimulated with mitogens contain high amounts of IL-6 and interferon-g (IFN-g), whereas the tumor necrosis factor-a is produced in normal concentrations (Al-Janadi et al, 1993) . Patients with SS show elevated concentrations of serum IL-6 (Pettersson et al, 1992) and a decrease in the production of IFN-g, IL-1 and IL-2 (Kroemer & Martínez, 1991; Shiozawa et al, 1990) . T lymphocytes obtained from peripheral blood of individuals with SS produce less IL-2 when stimulated in vitro with mitogens and express a reduced number of IL-2 receptors (IL-2R) in their membranes as compared with healthy subjects. The reduction in IL-2 and IL-2R synthesis is possibly associated with a reduction in mRNA concentration for both proteins (AlJanadi et al, 1993; Struyf et al, 1990) .
Reduction in prostaglandin (PG) E1 synthesis is considered another important factor for the development of this disease, since it stimulates suppressor T lymphocytes (Horrobin, 1984; Horrobin & Campbell, 1980) . As a result, supplementation of SS patients with essential fatty acids, pyridoxine and vitamin C has been used to stimulate PGE-1 synthesis, resulting in an improvement of the rates of lacrimal and salivary production in these individuals (Horrobin & Campbell, 1980; Horrobin et al, 1981; Horrobin et al, 1979) . On the other hand, vitamin B 6 -deficient elderly subjects without SS show a decrease in IL-2 production that is reversed by supplementation with vitamin B 6 (Meydani et al, 1991) .
The objective of the present work was to study the vitamin B 6 nutritional status in patients with primary SS by assessing the consumption and the biochemical indicators of pyridoxine, and to determine whether pyridoxine supplementation to SS patients alters IL-2 production and specific mRNA expression of this cytokine in T lymphocytes stimulated or not with phytohemagglutinin (PHA).
Materials and methods
According to the two objectives, the study was divided into two parts: study I and study II.
Study I. Assessment of the nutritional pyridoxine status in patients with primary Sjögren's syndrome Twenty-one patients with primary SS were studied, 19 women and two men, with an average age of 53.7 y (range 28 -70 y). The average time of evolution of the disease was 8.4 y (range 1 -25 y). Patients were recruited from the Department of Immunology and Rheumatology of the Instituto Nacional de Ciencias Médicas y Nutricion. Recruitment of primary SS patients took approximately 1 y. Diagnosis of SS was established according to the following criteria: (1) keratoconjunctivitis sicca (demonstrated by Schirmer test < 5 mm=5 min, and=or characteristic corneal and conjunctival epithelial staining with rose bengal observed through a slit lamp); (2) minor salivary biopsy of the lower lip, focus score of ! 1=mm 2 , and=or abnormalities in sialography and=or scintigraphy; and (3) exclusion of other primary connective tissue disease or an autoimmune disease by pertinent clinical and serological studies (Fox et al, 1986; Kraus et al, 1992; Soto-Rojas et al, 1998) ; presence of another metabolic or autoimmune disease was excluded by clinical and serological assessment. Exclusion criteria also included the use of vitamin supplements or any other medication that interfered with pyridoxine metabolism mainly isoniazid and hydralazine. Subjects were clinically examined each month, and no clinical differences or the presence of infections were observed during the study This was a cross-over double blind placebo-pyridoxine study divided into four phases: (a) a pretreatment phase for 3 months (time 7 3 to 0 months, phase I); (b) a 3 month period with the supplementation of the vitamin or placebo (time 0 to þ 3 months, phase II); (c) a 'washing' period of 1 month without treatment (time þ 3 to þ 4 months, phase III); and (d) a 3 month period with the alternate treatment (time þ 4 to þ 7 months, phase IV). During phase II patients were randomly assigned to group A (n ¼ 12) initially supplemented with vitamin B 6 , or group B (n ¼ 9) initially receiving placebo.
Pyridoxine status and Sjögren syndrome AR Tovar et al Vitamin B 6 's biochemical status was assessed at the beginning of the pretreatment phase, and at the beginning, middle and end of the two treatment periods. Dietary surveys were done at the beginning and at the end of each treatment period.
The vitamin supplement was manufactured by Productos Roche (México) as 25 mg of pyridoxine tablets. Placebo tablets contained only the excipient and they were identical in color and shape to the vitamin supplement. Each patient consumed one tablet per day of the vitamin supplement or placebo during the treatment periods of the protocol. The daily 25 mg dosage was chosen because preliminary studies in our Institution revealed that this amount was enough to correct the biochemical deficiency of pyridoxine in different clinical conditions without producing toxic effects.
Nutrient intake was assessed by a 24 h recall method complemented with 7 day food frequency records. Macronutrient content of the diet was calculated by using tables of Mexican food composition (Hernández et al, 1977) and pyridoxine content was calculated based in Handbook 8 of the United States Department of Agriculture (1985) .
Antecubital vein blood samples (5 ml) were taken in the fasting state. Blood samples were centrifuged at 1300 g for 15 min at room temperature. Plasma and white cells were removed, and erythrocytes were washed with 2 -3 vols of PBS and centrifuged again under the same conditions. The supernatant was discarded, the erythrocyte pellet was aliquoted (200 ml) in vials, protected against light, and frozen at 7 20 C for no more than 2 weeks, until the day of the assay. Vitamin B 6 status was assessed according to Stanulovic et al, (1967) , by measuring in duplicate erythrocyte aspartate amino transferase (eAAT) activity, with and without the in vitro addition of pyridoxal-5' phosphate (PLP) to calculate the activation coefficient. Samples of 100 ml hemolizate were preincubated at 37 C in 2.8 ml of 15 mM Tris -HCl buffer, pH 7.6, containing 15 mM aspartate, 0.2 mM reduced b-nicotinamide adenine dinucleotide (NADH), and 62.5 units=ml malate dehydrogenase (Karmen, 1955) . Stimulation of the enzyme activity was achieved by addition of 300 ml of 0.61 mM PLP and incubating the reaction tubes for 15 min at 37 C (Stanulovic et al, 1967) . The reaction was initiated by the addition of 100 ml 0.2 M a-ketoglutarate. The eAAT activity was expressed as micromoles of NADH oxidized=ml erythrocytes=h, and the activation coefficient (eAAT-AC) was calculated as follows:
eAAT-AC = eAAT activity (+PLP)/eAAT activity (-PLP) An eAAT-AC < 1.8 as established by Leklem is associated with an adequate pyridoxine status, whereas an eAAT-AC ! 1.8 is considered as indicator of biochemical pyridoxine deficiency (Leklem, 1990) .
Study II. Effect of pyridoxine on IL-2 production in patients with Sjögren's syndrome Twelve patients with primary SS selected as in study I and 14 clinically healthy adult volunteers (controls) matched by age and sex were studied. Exclusion criteria for control subjects were the use of vitamin supplements or any other medication that interfered with pyridoxine metabolism 6 months previous to the study. At the beginning of the study, 40 ml of blood were extracted from all patients and controls to measure eAAT activity and its activation coefficient, as well as to quantitate in vitro production of IL-2 and its mRNA from stimulated lymphocytes. Patients and controls were then randomly assigned to two groups, one supplemented daily with 25 mg vitamin B 6 and the other with placebo for 45 days. At the end of this period and 1 month after suspending the pyridoxine or placebo treatment, a 40 ml blood sample was taken to measure the same parameters. The protocol of both studies was previously approved by the Bioethics Research Committee of the Instituto Nacional de Ciencias Médicas y Nutrició n Salvador Zubiran, and all subjects signed an informed consent.
Pyridoxine status was assessed by measuring eAAT activity and its activation coefficient as described above. Lymphocytes were obtained by a Ficoll gradient (Boyum, 1968) . T lymphocytes were separated by forming E rosettes with sheep red blood cells previously sensitized with AET solution (Coligan et al, 1992) . Aliquots of 2Â10 6 T lymphocytes were cultured in RPMI medium supplemented with calf fetal serum, antibiotics (penicillin and streptomycin), and glutamine in the presence or absence of PHA. Cells were incubated at 37 C in 5% CO 2 for 24 h. Then, cells were centrifuged at 2500 rpm for 14 min, and the supernatants were frozen at 7 20 C until IL-2 concentration was quantified. On the other hand, cells were frozen at 7 70 C for IL-2 mRNA quantitation. IL-2 concentration was assayed by ELISA using the kit for human IL-2 Quantikine (R&D Systems, Minneapolis, MN, USA). Detection of IL-2 mRNA was performed by reverse-transcriptase polymerase chain reaction (RT-PCR). The oligonucleotide sense and antisense primer sequences for IL-2 were 5 0 GTC ACA AAC AGT GCA CCT AC 3 0 and 5 0 ATG GTT GCT GTC TCA TCA GC 3 0 , respectively. Primers were synthesized with the oligo 1000 DNA synthesizer (Beckman, Palo Alto, CA, USA). Total RNA was extracted (Chomczynski, 1993) with trizol reagent (Life Technologies, Gathesburg, MD, USA) and quantified spectrophotometrically. Integrity of RNA was established by detection of 18 and 28S bands in agarose -formaldehyde gels, as well as with b-actin primers.
RT-PCR. The extracted RNA (5 mg) was reverse transcribed to cDNA with Moloney Murine Leukemia Virus (M-MLV) reverse transcriptase (RT; Gibco BRL, Life Technologies Gaithersburg, MD, USA). Reactions were performed in the presence of 400 mmol=l of each dNTP (Gibco BRL, Life Technologies), 0.01 mg Oligo-dT, 10 mmol=l dithiotreitol, 10 U=ml RNase inhibitor, and 50 U of M-MLV-RT. The final volume was adjusted to 10 ml of DEPC-H 2 O. The reaction mix was incubated 1 h at 42 C, M-MLV-RT was heat inactivated for 5 min at 94 C. The cDNA was amplified in the presence of 2 U Taq DNA polymerase (Gibco BRL, Life Technologies), 5 ml Pyridoxine status and Sjögren syndrome AR Tovar et al of 2 mmol=l each dNTP, 5 ml of 10ÂPCR buffer (500 mmol=l KCl in 200 mmol=l Tris -HCl, pH 8.4) containing 15 mmol=l MgCl 2 , 3 ml of 10 mmol=l each sense and antisense oligonucleotides, and 24 ml of water. The reaction conditions were 95 C for 5 min followed by 33 cycles, each consisting of 1 min at 95 C, 1 min at 55 C, 1 min 30 s at 72 C, followed by a single cycle extension for 7 min at 72 C. The PCR products were separated on 1.5% agarose gel, visualized with ethidium bromide staining, and signals were analyzed and quantified by densitometry. Signals were normalized to those of b-actin.
Statistical analysis
Data are shown as mean AE standard error (s.e.). In study I the timeÂtreatment interaction was statistically assessed by twoway ANOVA, followed by Scheffe's test to determine significant differences among groups. In study II, the timeÂtreat-treatmentÂhealth status interaction was statistically assessed by three-way ANOVA, followed by the Bonferroni=Dunn test to determine significant differences among groups. P-values for interactions are reported and the significance level was set at P < 0.005.
Results

Study I. Assessment of pyridoxine nutritional status in patients with Sjögren's syndrome
Dietary assessment. The RDA for pyridoxine is 2 mg=day. As shown in Table 1 , the average daily intake of pyridoxine was low in both groups and non-significantly different, and remained low during the study. On the other hand, mean energy and protein intake of subjects in both groups was 7315 kJ=day (1750 kcal=day) and 63 g=day, respectively, and did not change during the study. Table 2 shows the activation coefficients for eAAT during the study. In both groups the activation coefficient for this enzyme was above 1.8 at the beginning of the study (phase I), which indicates according to Leklem (1990) , that all patients had biochemical deficiency of this vitamin.
Supplementation with pyridoxine to group A (phase II) and group B (phase IV) produced a significant reduction of the activation coefficients to normal values, indicating biochemical recovery of pyridoxine nutritional status. There was a significant timeÂtreatment interaction (P < 0.0001).
After not receiving pyridoxine for 1.5 months during the washing period, patients of group A developed again biochemical deficiency of vitamin B 6 .
Study II. Effect of pyridoxine on IL-2 production in patients with Sjögren's syndrome Table 3 shows the activation coefficients of aspartate aminotransferase in SS patients and in control subjects. There was a significant interaction between timeÂtreatmentÂhealth status assesed by three-way ANOVA (P < 0.05). Patients with SS showed significant biochemical deficiency of vitamin B 6 , which was corrected after being treated with 25 mg of vitamin B 6 =day for 45 days and remained adequate despite discontinuing pyridoxine supplement intake for a month (P < 0.01). On the other hand, those SS patients treated with placebo continued showing activation coefficients above two, indicating vitamin B 6 deficiency during the three evaluations. Control subjects had adequate initial eAAT-AC that nevertheless decreased significantly with pyridoxine supplementation, whereas the activation coefficient of eAAT in control subjects receiving placebo was not altered.
IL-2 was not detected in lymphocytes cultured without PHA stimulation in any of the groups studied. Although Pyridoxine status and Sjögren syndrome AR Tovar et al pyridoxine supplementation significantly improved the nutritional status of this vitamin, it did not significantly affect the production of IL-2 in cultured lymphocytes stimulated with PHA (Table 4) . Furthermore, IL-2 mRNA was not detected by RT-PCR in lymphocytes from subjects of both groups without in vitro PHA stimulation. This could explain the absence of this cytokine in the supernatant of cultured lymphocytes in their basal state. Stimulation of cultured lymphocytes with PHA induced expression of IL-2 mRNA; however, there was no difference between both groups (Figure 1 ).
Discussion
In the present work (study I), we found that SS patients had biochemical deficiency of pyridoxine as evidenced by altered eAAT-AC, which was corrected by supplementation with 25 mg of vitamin B 6 per day during 3 months. However, IL-2 and its mRNA production in vitro by PHA-stimulated T lymphocytes were not significantly different to those of healthy controls and were independent from the pyridoxine status (study II).
Information on vitamin B 6 status in the Mexican population is scarce and limited to specific studies. Biochemical pyridoxine deficiency has been observed in Mexican rural dwellers with marginal nutrition status (Tovar et al, 1985) ; except for pregnant women (Tovar et al, 1996) and in-women using oral contraceptives (Tovar et al, 1985) , biochemical deficiency is less evident in urban areas. No information on vitamin B 6 status from Mexican patients with different pathologies, including autoimmune diseases, is available.
In the present study, eAAT-AC was sensitive to both pyridoxine deficiency and recovery through supplementation. Biochemical deficiency in SS patients was associated with dietary intakes below the RDA for this vitamin, which could be explained by the distortions in eating habits that, in our experience, are often seen in this type of patients as a Figure 1 Expression of IL-2 mRNA in lymphocytes with and without stimulation in vitro with PHA from patients with primary Sjögren's syndrome (SS) and controls. Expression of IL-2 was assessed by the reverse-transcriptase polymerase chain reaction assay, and amplified products were electropheresed in a 1% agarose gel stained with ethidium bromide. This assay was performed in each patient and control subject.
Pyridoxine status and Sjögren syndrome AR Tovar et al consequence of the oral manifestations of the disease. However, it is not possible in this study to associate the symptoms of eating discomfort due to xerostomia in SS patients with the biochemical deficiency of vitamin B 6 , although the possibility cannot be ruled out that the deficiency of this nutrient may worsen the symptoms. Biochemical deficiency of vitamin B 6 in SS patients could also be associated with gastric involvement. Despite dysphagia, athrophic changes in the antrum, gastric inflammation and celiac disease being reported in SS patients (Alvarez-Celorio et al, 2000) , in general they are very uncommon. Nonetheless, the extent of vitamin B 6 absorption and B 6 production by intestinal bacterial flora in SS patients remains unknown and there could also be a hypothetical abnormality that could explain the biochemical deficiency of pyridoxine observed in these subjects. It has been found that patients with primary SS show alterations in the functional properties of peripheral blood Tcells, and changes in regulatory T-cell subset balance in peripheral blood that can contribute to the immunopathogenesis of this disease (Aziz et al, 1994) . Furthermore, it is known that IL-2 and IL-2R mRNA are expressed by most primary SS affected tissues, and their expression is independent of the severity and extension of infiltration (Boumba et al, 1995) . In fact, IL-2 is a marker of activated T-cells and, although IL-2 production by peripheral blood lymphocytes from primary SS patients is decreased as compared to normal controls, local production of IL-2 may play a significant role in the local histopathologic lesion (Alcocer-Varela et al, 1984) . However, in our study we did not find differences in IL-2 production from T lymphocytes stimulated in vitro with PHA between controls and primary SS patients.
Pyridoxine deficiency is associated with several changes in the immune response, including IL-2 production. In a group of elderly patients, Meydani et al (1991) showed that pyridoxine deficiency reduced the mitogenic response to PHA and Con A as well as the IL-2 production of peripheral mononuclear cells and that supplementation with the vitamin reverted these alterations. The possible mechanism for the effect of vitamin B 6 on IL-production is not known, but a deficiency of this vitamin has been shown to alter the percentage of T helper cells (Van den Berg et al, 1998) and the synthesis of DNA and RNA (Axelrod & Trakatellis, 1964) , which would indirectly affect IL-2 production. Also, in elderly subjects, pyridoxine supplementation has been shown to increase production of T helper lymphocytes (Talbott et al, 1987) . The production of IL-2 from T-cells stimulated with PHA is profoundly affected when cells are incubated in the presence of the vitamin B 6 antagonist 4-deoxypyridoxine (Trakatellis et al, 1992) ; however T lymphocytes from subjects treated with isoniazid do not show this response (Ravn et al, 1995) .
In our study we did not find decreased production of IL-2 and its mRNA in PHA-stimulated lymphocytes from pyridoxine deficient patients. A possible explanation is that vitamin B 6 deficiency was only subclinical (biochemical), and it was not severe enough to affect T lymphocytes. Thus, it is necessary to establish, at the molecular level, the specific metabolic mechanisms in T-cells that are affected by vitamin B 6 deficiency, and what is the impact of a severe vs a biochemically subclinical deficiency.
